cancer, and in human epidermal growth factor 2 (HER2)-positive breast cancer, particularly when trastuzumab is added to the treatment regimen. The patients who achieve axillary pCR, show better loco-regional and survival outcomes, irrespective of the primary tumor response [4, 5, 7, [10] [11] [12] [13] [14] [15] [16] . NAT also provides adequate time for genetic testing, and planning for breast reconstruction, when indicated. Furthermore, it provides information to assess the in vivo response to therapy [2, 11] .
The benefit of NAT, which is the focus of this article, lies in the opportunity to offer SLNB instead of ALND in patients with node positive breast cancer that was cleared by NAT. This consequently saves patients from the harmful outcomes of ALND [2] .
The cons of NAT include both, the possibilities of over-and under-treatment. This depends on the errors in correct estimation of the extent of disease prior to, or after NAT. The possibility of disease progression during therapy also exists, particularly in chemo-resistant tumors. However, there is no significant difference in 15-year distant recurrence between NAT and adjuvant treatment. Post-NAT under-treatment can be limited by a detailed pathological assessment, meticulous tumor localization, and appropriate radiotherapy [2, 14, 17] .
In terms of prognosis, the response of the axillary nodes to NAT is known to be a more important factor, than the initial axillary status. The false-negative rates (FNRs) of SLNB after NAT range from 5% to 30%, but these FNRs can be reduced to less than 10% when the dual technique for SLN localization is used, and when more than two LNs can be dissected and examined [6,8,10,11,18-21].
At least 28% of all candidates from all breast cancer subtypes achieve pCR in both, the breast, and axillary tumor, with the highest pCR rate in hormone negative, HER2-positive breast cancer, and the lowest rate in luminal A subtype [17, 22] . The rates for axillary pCR are higher, reaching up to 37% (between 5% and 75%). This rate reaches up to 21% in patients with estrogen receptor-positive/HER2-negative tumors, 60% in triple negative tumors, between 67% and 73% in HER2-positive tumors when trastuzumab is used in combination with chemotherapy, and up to 97% when dual HER2 blockage is applied [7, 8, 10, 11, 15, 16, 20, 23, 24] .
Considering its significant effect on minimizing the complications and morbidities of ALND, SLNB can be considered as a goal rather than as a tool. Axillary complete pathological response can be achieved after NAT in at least 21% of luminal A, and, up to 97% of HER2-positive subtypes of node positive breast cancer. Every node positive breast cancer patient receives chemotherapy, either in the neoadjuvant or adjuvant setting. There is no significant advantage for receiving it in the adjuvant setting as compared with NAT. NAT should therefore be adopted to be the standard of care for every node positive breast cancer patient.
